AXIM Biotechnologies, Inc. Stock Other OTC
Equities
AXIM
US05463V1008
Biotechnology & Medical Research
Sales 2022 | 8.88K 12.11K | Sales 2023 | 39.52K 53.92K | Capitalization | 4.52M 6.16M |
---|---|---|---|---|---|
Net income 2022 | -6M -8.19M | Net income 2023 | -8M -10.92M | EV / Sales 2022 | 1,218 x |
Net Debt 2022 | 5.64M 7.7M | Net Debt 2023 | 5.74M 7.83M | EV / Sales 2023 | 259 x |
P/E ratio 2022 |
-0.69
x | P/E ratio 2023 |
-0.48
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 71.61% |
Managers | Title | Age | Since |
---|---|---|---|
John Huemoeller
CEO | Chief Executive Officer | 68 | - |
Robert Malasek
DFI | Director of Finance/CFO | 55 | 16-06-28 |
Kurt Phinney
COO | Chief Operating Officer | - | 23-05-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Huemoeller
CEO | Chief Executive Officer | 68 | - |
Timothy Scott
BRD | Director/Board Member | 71 | 17-05-17 |
Director/Board Member | 76 | 17-05-17 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |